When parts of the small intestine are diseased or die, the treatment can involve surgically removing the affected tissue. Although lifesaving, the procedure—referred to as a radical small bowel ...

- 4Q 2025 net income available to common shareholders of $100.2 million, or $2.79 Earnings per Share ("EPS"). Full year 2025 net income available to common shareholders of $406.9 million, or $11.40 ...

Gentle yet powerful, peptide serums boost collagen, hydrate deeply, and deliver visible firmness. We tested the top picks from editors and dermatologists.

Q4 2025 Earnings Call March 5, 2026 12:15 PM ESTCompany ParticipantsLucian Grainge - Chairman & CEOMichael Nash ...

Good day, and welcome to today's conference call to discuss Stratasys' Fourth Quarter and Full Year 2025 Financial Results. My name is Donna, and I'm your operator for today. [Operator Instructions] ...

The unaudited financial and operational information included in this press release is subject to potential adjustments and is based on the information available to management at this time. Potential ...

On the call with us today are our CEO, Dr. Yoav Zeif, and our CFO, Eitan Zamir. Please note that some of the information you will hear during our discussion today will consist of forward-looking ...

K arnataka Budget Session Today, CM Siddaramaiah’s 17th Karnataka Budget 2026 Key Announcements & Highlights: Karnataka Chief ...

Positive results from Phase 3 ADAPT OCULUS study show VYVGART’s potential as the first targeted treatment for patients living with ocular MG ...

This paper examines whether Chinese development finance is associated with faster progress toward Millennium Development Goal style targets in low- and middle-income countries. We combine AidData’s ...

Enrollment remains on track in Phase 2 pivotal portion of PYNNACLE trial evaluating rezatapopt as monotherapy in platinum-resistant/refractory ovarian cancer patients with a TP53 Y220C mutationRezatap ...